Statins as modulators of bone formation

Arthritis Research

Volumn 4, Issue 3, 2002, Pages 151-153

  Edwards, Christopher J ^a   Spector, Tim D ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Bone morphogenetic proteins; Fracture; Inflammation; Statins

Indexed keywords

ALKALINE PHOSPHATASE; ANTILIPEMIC AGENT; ATORVASTATIN; BONE MORPHOGENETIC PROTEIN 2; C REACTIVE PROTEIN; CHOLESTEROL; CORTICOSTEROID; ESTROGEN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAVASTATIN; MEVALONIC ACID; MEVINOLIN; MINERAL; NITROGEN; OSTEOCALCIN; PHOSPHONIC ACID DERIVATIVE; PITAVASTATIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BONE DENSITY; BONE MALFORMATION; CELL ACTIVITY; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG SCREENING; FEMALE; FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OSSIFICATION; OSTEOBLAST; RAT; RISK ASSESSMENT; STEM CELL;

BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; BONE MORPHOGENETIC PROTEINS; FEMALE; FRACTURES, BONE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; NEOVASCULARIZATION, PATHOLOGIC; OSTEOBLASTS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0036242398     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar399     Document Type: Article

References (20)

1. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
2. Stimulation of bone formation in vitro and in rodents by statins
3. Oral statins and increased bone-mineral density in postmenopausal women
4. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
5. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
6. HMG-CoA reductase inhibitors and the risk of fractures
7. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial
8. Use of statins and risk of fractures
9. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
10. Statin use and fracture: A meta-analysis of 8 observational studies
11. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells
12. Pitavastatin enhanced bmp-2 and osteocalcin expression by inhibition of rho-associated kinase in human osteoblasts
13. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells
14. Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events
15. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
16. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
17. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
18. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway
19. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease
20. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study